MX2021000461A - Derivados de tiadiazina. - Google Patents

Derivados de tiadiazina.

Info

Publication number
MX2021000461A
MX2021000461A MX2021000461A MX2021000461A MX2021000461A MX 2021000461 A MX2021000461 A MX 2021000461A MX 2021000461 A MX2021000461 A MX 2021000461A MX 2021000461 A MX2021000461 A MX 2021000461A MX 2021000461 A MX2021000461 A MX 2021000461A
Authority
MX
Mexico
Prior art keywords
thiadiazine derivatives
racemates
diastereomers
solvates
hydrates
Prior art date
Application number
MX2021000461A
Other languages
English (en)
Inventor
Éles János
István Ledneczki
Pál Tapolcsányi
Zsolt Némethy
György István Lévay
Erszébet Jablonkai
Eszter Gábor
András Visegrádi
József Levente Petro
György Selényi
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of MX2021000461A publication Critical patent/MX2021000461A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Derivados de tiadiazina o sales, metabolitos biológicamente activos, profármacos, racematos, enantiómeros, diastereómeros, solvatos o hidratos farmacéuticamente aceptables de éstos, así como composiciones farmacéuticas que los contienen y su uso como moduladores de la actividad del receptor nicotínico de acetilcolina a7 en un sujeto mamífero.
MX2021000461A 2018-07-13 2019-07-12 Derivados de tiadiazina. MX2021000461A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP1800249A HU231414B1 (hu) 2018-07-13 2018-07-13 Tiadiazin származékok
PCT/IB2019/055949 WO2020012423A1 (en) 2018-07-13 2019-07-12 Thiadiazine derivatives

Publications (1)

Publication Number Publication Date
MX2021000461A true MX2021000461A (es) 2021-06-23

Family

ID=89992726

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000461A MX2021000461A (es) 2018-07-13 2019-07-12 Derivados de tiadiazina.

Country Status (22)

Country Link
US (1) US20210267993A1 (es)
EP (1) EP3820865A1 (es)
JP (2) JP7440486B2 (es)
KR (1) KR20210033003A (es)
CN (1) CN112424198A (es)
AR (1) AR115783A1 (es)
AU (1) AU2019300515A1 (es)
BR (1) BR112020027016A2 (es)
CA (1) CA3104264A1 (es)
CL (1) CL2021000081A1 (es)
CO (1) CO2021001224A2 (es)
CU (1) CU24622B1 (es)
EA (1) EA202190246A1 (es)
GE (1) GEP20237459B (es)
HU (1) HU231414B1 (es)
IL (1) IL279939A (es)
MX (1) MX2021000461A (es)
PE (1) PE20210465A1 (es)
PH (1) PH12021550007A1 (es)
SG (1) SG11202012769QA (es)
TW (1) TWI827628B (es)
WO (1) WO2020012423A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021163513A1 (en) * 2020-02-14 2021-08-19 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Heat shock protein modulators and anti-huntington disease therapeutic agents
TW202202495A (zh) 2020-03-26 2022-01-16 匈牙利商羅特格登公司 作為ｇａｍｍａ－胺基丁酸Ａ受體次單元ａｌｐｈａ ５受體調節劑之㖠啶及吡啶并〔３，４－ｃ〕嗒𠯤衍生物
CN111454232B (zh) * 2020-05-30 2021-11-23 南方医科大学 一种1,3,4-噻二嗪类化合物及其应用
HUP2100338A1 (hu) 2021-09-29 2023-04-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2617394C (en) 2005-09-13 2014-06-03 Janssen Pharmaceutica N.V. 2-aniline-4-aryl substituted thiazole derivatives
CN101815512B (zh) 2007-10-04 2013-04-24 弗·哈夫曼-拉罗切有限公司 环丙基芳基酰胺衍生物和其用途
CA2701214C (en) 2007-10-04 2016-08-02 F. Hoffmann-La Roche Ag Tetrazole-substituted aryl amide derivatives and uses thereof
RU2010137114A (ru) 2008-02-07 2012-03-20 Эбботт Лэборетриз (Us) Амидные производные как позитивные аллостерические модуляторы и способы их применения
ES2442932T3 (es) 2008-03-19 2014-02-14 Janssen Pharmaceutica N.V. 1,2,4-Triazoles trisustituidos como moduladores de receptores nicotínicos de acetilcolina
JP2011516599A (ja) 2008-04-17 2011-05-26 グラクソ グループ リミテッド ニコチン性アセチルコリン受容体サブタイプα７のモジュレーターとしてのインドール類
EA018187B1 (ru) 2008-05-09 2013-06-28 Янссен Фармацевтика Нв Тризамещенные пиразолы в качестве модуляторов рецепторов ацетилхолина
CA2776835A1 (en) * 2009-10-13 2011-04-21 Msd Oss B.V. Condensed azine - derivatives for the treatment of diseases related to the acetylcholine receptor
JP5865397B2 (ja) * 2011-02-03 2016-02-17 ルピン・リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ α７ｎＡＣｈＲのモジュレータとして使用されるピロール誘導体
EP2970180A1 (en) * 2013-03-13 2016-01-20 Lupin Limited Pyrrole derivatives as alpha 7 nachr modulators
DK3433234T3 (da) * 2016-03-22 2022-01-03 Merck Sharp & Dohme Allosteriske modulatorer af nicotinacetylcholinreceptorer
JP7041141B2 (ja) 2016-11-01 2022-03-23 メルク・シャープ・アンド・ドーム・コーポレーション 置換された二環式ヘテロアリール系ニコチン性アセチルコリン受容体アロステリック調節剤
WO2018160878A1 (en) * 2017-03-02 2018-09-07 Assembly Biosciences, Inc. Cyclic sulfamide compounds and methods of using same

Also Published As

Publication number Publication date
CU20200109A7 (es) 2021-08-06
AU2019300515A1 (en) 2021-02-11
PH12021550007A1 (en) 2021-09-20
JP7440486B2 (ja) 2024-02-28
CA3104264A1 (en) 2020-01-16
JP2024056879A (ja) 2024-04-23
IL279939A (en) 2021-03-01
TWI827628B (zh) 2024-01-01
EP3820865A1 (en) 2021-05-19
TW202019431A (zh) 2020-06-01
PE20210465A1 (es) 2021-03-08
BR112020027016A2 (pt) 2021-04-06
GEP20237459B (en) 2023-01-25
JP2021529813A (ja) 2021-11-04
EA202190246A1 (ru) 2021-04-20
AR115783A1 (es) 2021-02-24
HUP1800249A2 (en) 2020-01-28
US20210267993A1 (en) 2021-09-02
CL2021000081A1 (es) 2021-10-29
CN112424198A (zh) 2021-02-26
CO2021001224A2 (es) 2021-02-17
KR20210033003A (ko) 2021-03-25
WO2020012423A1 (en) 2020-01-16
SG11202012769QA (en) 2021-02-25
HU231414B1 (hu) 2023-08-28
CU24622B1 (es) 2022-09-08

Similar Documents

Publication Publication Date Title
MX2021000461A (es) Derivados de tiadiazina.
MX2023001311A (es) Agonistas heterociclicos de glp-1.
PH12020552183A1 (en) Spirochromane derivatives
MX2022009524A (es) Agonistas heterociclicos de glp-1.
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
CR20210627A (es) Derivados de benzisoxazol sulfonimada
MX2021012903A (es) Moduladores de la via de respuesta integrada al estres.
PH12019502562A1 (en) N-substituted indole derivatives
GB0701366D0 (en) Novel pharmaceutical compositions
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
MX2021004940A (es) Derivados de piridinil sulfonamida, composiciones farmaceuticas y usos de estos.
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
PH12019501968A1 (en) PHARMACOLOGICALLY ACTIVE ALICYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES
PH12020551341A1 (en) 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof
MX2023009285A (es) Compuestos novedosos.
MX2020013291A (es) Derivados de piridinilo alcoxisustituido como antagonistas del receptor lpa1 y su uso en el tratamiento de la fibrosis.
TW200724143A (en) Novel compounds for the treatment of inflammatory diseases
MX2023005371A (es) Moduladores de receptor gamma activado por proliferador de peroxisoma (ppar gamma) y metodos de uso.
NZ763341A (en) Polycyclic amides as muscarinic m1 receptor positive allosteric modulators
JOP20220082A1 (ar) مشتقات 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4
ZA202203108B (en) Indole carboxamide compounds and use thereof for the treatment of mycobacterial infections
ZA202203106B (en) Thiazole carboxamide compounds and use thereof for the treatment of mycobacterial infections
MX2021015727A (es) Derivados de piridin-3-ilo.
MX2021004471A (es) Derivados de pirrolo-pididazina como moduladores alostéricos positivos del receptor muscarínico m1.
ZA202206436B (en) Macrocyclic pantetheine derivatives and uses thereof